Table 1. MSC protects against toxicities induced by CTX, CDDP, oxaliplatin, and irinotecan in Fischer rats.
| |
Toxicity (% of total) |
|||
|---|---|---|---|---|
| Treatment (mg kg−1) | MWLa | Diarrhoea | Stomatitis | Lethality |
| Control |
2.1±0.6 |
0 |
0 |
0 |
| MSC (0.75) |
5.8±1.2 |
0 |
0 |
0 |
| CTX (100) |
9.9±1.6 |
0 |
0 |
0 |
| CTX (100) + MSC (0.75) |
6.6±3.0* |
0 |
0 |
0 |
| CTX (150) |
18.5±3.0 |
50 |
38 |
62 |
| CTX (150) + MSC (0.75) |
16.6±1.2* |
0*** |
0*** |
25** |
| CDDP (6) |
13.5±2.4 |
50 |
0 |
0 |
| CDDP (6) + MSC (0.75) |
10.6±2.1* |
0*** |
0 |
0 |
| CDDP (9) |
21.9±2.8 |
100 |
75 |
100 |
| CDDP (9) + MSC (0.75) |
13.5±2.4** |
0*** |
0*** |
0*** |
| Oxal (20) |
20.8±5.3 |
0 |
0 |
100 |
| Oxal (20) + MSC (0.75) |
9.4±2.6 |
0 |
0 |
0 |
| Irinotecan (200) |
22.5±3.2 |
30 |
0 |
100 |
| Irinotecan (200) + MSC (0.75) | 10.5±1.5 | 0 | 0 | 0 |
Abbreviations: CDDP=cis-diamminedichloroplatinum; CTX=cyclophosphamide; MSC=Se-methylselenocysteine; MWL=mean weight loss; Oxal=oxaliplatin.
*P< 0.05, **P< 0.01 and ***P< 0.001 when compared with the drug-alone-treated group.
CTX and CDDP were administered as a single intravenous (i.v.) injection and MSC by oral route (p.o.) daily for 21 days, with the first dose having started 14 days before CTX, CDDP, Oxal, or irinotecan treatment. Irinotecan was administered i.v. weekly × 4. Each group had 12–24 rats in total, from 3 to 6 independent experiments.
a
Mean weight loss± s.d.